Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards

Rheumatology (United Kingdom)

Volumn 54, Issue 1, 2014, Pages 144-151

  Khanna, Dinesh ^a   Furst, Daniel E ^b   Allanore, Yannick ^c,d   Bae, Sangmee ^b   Bodukam, Vijay ^e   Clements, Philip J ^b   Cutolo, Maurizio ^f   Czirjak, Laszlo ^g   Denton, Christopher P ^h   Distler, Oliver ⁱ   Walker, Ulrich A ^j   Matucci Cerinic, Marco ^k,l   Müller Ladner, Ulf ^m   Seibold, James R ⁿ   Singh, Manjit ^o   Tyndall, Alan ^j  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d université Paris Cité   (France)

^e CROZER CHESTER MEDICAL CENTER   (United States)

^f UNIVERSITY OF GENOA   (Italy)

^g UNIVERSITY OF PÉCS   (Hungary)

^h ROYAL FREE HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^j UNIVERSITY OF BASEL   (Switzerland)

^k CAREGGI UNIVERSITY HOSPITAL   (Italy)

^l UNIVERSITY OF FLORENCE   (Italy)

^m JUSTUS LIEBIG UNIVERSITY   (Germany)

ⁿ Scleroderma Research Consultants   (United States)

^o Rochester General Health System   (United States)

more..

Author keywords

Clinical trials; Points to consider; Systemic sclerosis

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); CONSENSUS; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE DURATION; DISEASE SEVERITY; EVIDENCE BASED POINTS TO CONSIDER; FINGER ULCER; HUMAN; MEDICAL ETHICS; METHODOLOGY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCLERODERMA; SKIN FIBROSIS; SYSTEMIC SCLEROSIS;

EID: 84928719391     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu288     Document Type: Article

References (40)

1. Charles C, Clements PJ, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006;367: 1683-91.
2. Furst DE. Outcome measures in rheumatologic clinical trials and systemic sclerosis. Rheumatology 2008; 47(Suppl 5):v29-30.
3. Khanna D, Lovell DJ, Giannini E et al. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis 2008;67:703-9.
4. White B, Bauer EA, Goldsmith LA et al. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and outcomes in clinical trials in systemic sclerosis. Arthritis Rheum 1995; 38:351-60.
5. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005;26:587-95.
6. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117: 557-67.
7. Varga J. Antifibrotic therapy in scleroderma: extracellular or intracellular targeting of activated fibroblasts? Curr Rheumatol Rep 2004;6:164-70.
8. Baroni SS, Santillo M, Bevilacqua F et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354:2667-76.
9. Dougados M, Betteridge N, Burmester GR et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004;63:1172-6.
10. Khanna D, Distler O, Avouac J et al. Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol 2009; 36:2356-61.
11. Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
12. de Clerck LS, Dequeker J, Francx L et al. D-penicillamine therapy and interstitial lung disease in scleroderma. A long-term followup study. Arthritis Rheum 1987;30: 643-50.
13. Fuchs D, Fruchter L, Fishel B et al. Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis. Clin Rheumatol 1986; 5:527-30.
14. Scherbel AL, McCormack LJ, Layle JK. Further observations on the effect of dimethyl sulfoxide in patients with generalized scleroderma (progressive systemic sclerosis). Ann N Y Acad Sci 1967;141:613-29.
15. Tashkin DP, Elashoff R, Clements PJ et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007;176:1026-34.
16. Henness S, Wigley FM. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidencebased review. Curr Opin Rheumatol 2007;19:611-8.
17. Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. Lancet 2001;358:1119-23.
18. Matucci-Cerinic M, Denton CP, Furst DE et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011;70:32-8.
19. Tashkin DP, Elashoff R, Clements PJ et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
20. Nannini C, West CP, Erwin PJ et al. Effects of CYC on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and metaanalysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008;10: R124.
21. Clements PJ, Furst DE, Wong WK et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42:1194-203.
22. Seibold JR, Korn JH, Simms R et al. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000;132:871-9.
23. Schulz KF, Altman DG, Moher D. CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340: c332.
24. Beyer C, Distler JHW, Allanore Y et al. EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research. Ann Rheum Dis 2011;70:1178-82.
25. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
26. Johnson SR, Fransen J, Khanna D et al. Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) 2012;64:358-67.
27. Avouac J, Fransen J, Walker UA et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 2011;70: 476-81.
28. Cutolo M, Sulli A, Secchi ME et al. Nailfold capillaroscopy is useful for the diagnosis and follow-up of autoimmune rheumatic diseases A future tool for the analysis of microvascular heart involvement? Rheumatology 2006; 45(Suppl 4):iv43-6.
29. Medsger TA Jr, Silman AJ, Steen VD et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-67.
30. Boers M, Brooks P, Simon LS et al. OMERACT: an international initiative to improve outcome measurement in rheumatology. Clin Exp Rheumatol 2005;23(Suppl 39): S10-3.
31. Merkel PA, Clements PJ, Reveille JD et al. Current status of outcome measure development for clinical-trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol 2003;30:1630-47.
32. Furst DE, Khanna D, Matucci-Cerenic M et al. Scleroderma-developing measures of response. J Rheumatol 2005;32:2477-80.
33. Khanna D, Hays RD, Maranian P et al. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum 2009;61:1257-63.
34. Khanna D, Furst DE, Maranian P et al. Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. J Rheumatol 2011;38:1920-4.
35. Furst D, Khanna D, Matucci-Cerinic M et al. Systemic sclerosis-continuing progress in developing clinical measures of response. J Rheumatol 2007;34:1194-200.
36. Amjadi S, Maranian P, Furst DE et al. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum 2009;60:2490-8.
37. Khanna D, Furst DE, Hays RD et al. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis 2006;65:1325-9.
38. Nash RA, McSweeney PA, Crofford LJ et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007;110:1388-96.
39. Valentini G, Della Rossa A, Bombardieri S et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001;60:592-8.
40. Wong WK, Boscardin WJ, Postlethwaite AE et al. Handling missing data issues in clinical trials for rheumatic diseases. Contemp Clin Trials 2011;32:1-9.